Nature | 突破传统模型——内源振荡器塑造神经细胞命运，保证神经元仅生成一根轴突

TL;DR - A Nature paper from Frank Bradke's team (German Center for Neurodegenerative Diseases) shows that neuronal polarity — why a neuron grows exactly one axon — is driven by an intrinsic, soma-originated cytoskeletal oscillator rather than growth cones sensing external cues. This overturns the dominant extracellular-guidance model and names actomyosin contractility as a target for axon repair.

• Soma, not growth cone, is the control hub: live-cell imaging and embryonic brain slices show immature neurites undergo periodic alternating extension/retraction, with only one neurite elongating at a time, driven by ARP2/3-generated actin waves originating in the cell body — independent of extracellular guidance signals.
• ARP2/3 vs. myosin II antagonism: the actin wave first retracts all neurites; when it stochastically enters one neurite tip, local ARP2/3 weakens myosin-driven contraction and permits microtubule extension, giving that neurite axonal advantage. Myosin II acts as a global growth inhibitor, and ARP2/3 has position-dependent bidirectional function — reconciling previously contradictory results.
• Genetic and rescue evidence: ARP3 knockout abolishes actin waves and blocks axon formation; myosin inhibition rescues the knockout phenotype, indicating excessive actomyosin contraction is the core barrier to axon growth. The selected neurite eventually becomes ARP2/3-independent and grows continuously; the rest become dendrites.
• Significance: explains why neurons form a single axon despite a growth-factor-rich developmental environment, and proposes actomyosin contractility as a molecular target for spinal cord injury and neurodegenerative axon regeneration.

TL;DR - A Nature paper from Sarah-Maria Fendt's team (VIB, Belgium) reports that liver steatosis drives colorectal cancer liver metastases toward the poor-prognosis "replacement" growth pattern via a fatty-acid → MYC → proline → collagen axis, offering a metabolic explanation for metastasis heterogeneity and a patient-stratification biomarker. (Note: this item is biomedical research, not AI methodology.)

• In two treatment-naive CRC cohorts (155 Erasmus MC + 51 Göttingen), hepatic steatosis was the only patient variable independently associated with increased replacement-type metastases (5-yr OS 44.2% vs 73.4% for encapsulated).
• Mechanism: locally enriched liver-derived fatty acids (not systemic lipid levels) raise acetyl-CoA, increasing MYC K323 acetylation, which stabilizes MYC protein (post-transcriptional, no mRNA change) and transcriptionally activates P5CS/PYCR1/PYCR2 and COL1A1.
• Genetic proof: P5cs silencing abolished steatosis-induced replacement metastases; P5cs overexpression alone tripled them on control diet. Exogenous collagen or COL1A1 overexpression alone could not bypass the proline requirement. Consistent across CMT93, MC38, and CT26 models.
• Translation: MYC inhibitor MYCi975 selectively suppressed replacement-type metastases in vivo and in replacement-derived PDOs/PDX; retrospective analysis of the OMO-103 phase I trial showed response correlated with liver fat content rather than dose, suggesting steatosis as a stratification marker.

TL;DR - A Nature Biomedical Engineering paper (July 29, 2026) from UIUC reports in vivo CRISPR base editing that disrupts the exon 13 splice acceptor site in the HTT gene, producing a proteolysis-resistant huntingtin isoform that eases Huntington's disease pathology in rodent models. It matters as a precision genome-editing route that blunts mutant HTT toxicity without ablating the essential full-length protein.

• Disease rationale: CAG-repeat expansion in HTT exon 1 yields mutant HTT; caspase-6 cleavage at Asp586 generates aggregation-prone N-terminal fragments driving neuronal loss. The caspase-6 consensus site spans exons 12–13, so skipping either exon removes it.
• Approach: the team screened 140+ base editor variants targeting HTT splicing elements and identified platforms that disrupt the exon 13 splice acceptor (SA), inducing exon skipping and a cleavage-resistant HTT isoform.
• In vivo results: delivery to the striatum of transgenic HD rodent models reduced HTT fragment formation and mHTT aggregation, lessened brain atrophy, and improved functional deficits.
• Positioning: unlike total HTT knockdown, this preserves full-length HTT needed for normal cell function; results are preclinical (rodent) only, with no clinical data reported.

TL;DR - A Nature paper (published 2026-07-29, Mayo Clinic + Sanford Burnham Prebys) reports that mitochondrial metabolism and epigenetic regulation jointly drive the senescence-associated secretory phenotype (SASP), identifying the mitochondrial citrate transporter SLC25A1 as a druggable target that suppresses senescence-driven inflammation without clearing senescent cells. Note: this item is biomedical research with no AI/ML component.

• Mechanism: in senescent cells the mitochondrial pyruvate–citrate–acetyl-CoA axis is upregulated, raising acetyl-CoA availability that fuels histone acetylation at SASP gene loci; mtDNA/cGAS-STING signaling activates inflammatory transcription factors, but efficient SASP transcription still requires sufficient acetyl-CoA.
• Target: inhibiting SLC25A1 lowers histone acetylation and chromatin accessibility at SASP loci, limiting the inflammatory program.
• In vivo: SLC25A1 inhibition selectively dampened SASP-related inflammation in aged mice and extended healthspan without reversing/eliminating senescence — a shift away from the classic senolytic "clear the zombie cells" strategy.
• Framing: the authors describe a "mitochondrial metabolic checkpoint" that gates epigenetic execution of innate immune signaling. Paper: https://www.nature.com/articles/s41586-026-10791-2

TL;DR - A Zhejiang University team (Yi Cong, Zhu Guixin, Sun Qiming) reports in Nature Cell Biology (July 29, 2026) that the glycolytic enzyme PGAM1 doubles as a "metabolic–autophagy checkpoint," directly initiating autophagy independently of its catalytic activity. It matters because it links growth-promoting metabolism to stress survival and identifies a dual-function node that tumors hijack.

• PGAM1 acts as a molecular scaffold recruiting PI3K complex I to phagophore assembly sites, triggering autophagosome formation; this role is genetically required, evolutionarily conserved (shown in both yeast and mammalian systems), and functionally separable from glycolysis.
• The autophagy function is regulated by Atg1/ULK1-mediated phosphorylation, which strengthens Atg14 binding under nutrient starvation.
• In cancer, PGAM1 upregulation simultaneously boosts glycolytic flux and autophagic capacity; disrupting either function significantly suppresses tumor growth, framing PGAM1 as a homeostatic checkpoint co-opted to drive proliferation and stress resistance.
• Note: the item is a WeChat science-media write-up of the paper (link: nature.com/articles/s41556-026-02034-3); no quantitative data beyond the qualitative claims above is provided.